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Supplementary Figure 1 
Whole-genome sequencing coverage in tumours and matched-normal genomes in the PCAWG cohort. 
(a) Violin plot for the distribution of the mean coverage from all tumours (N=2,954) analyzed shows a bimodal distribution with maxima 
at 38 and 60 reads per base-pair. White point, median; box, 25th to 75th percentile (interquartile range, IQR); whiskers, data within 
1.5 times the IQR. (b) Tumour samples mean depth of coverage distribution by cancer type. The number of samples per tumour type is 
shown in parenthesis. Violin plot features are as in ‘a’. (c) Violin plot for the distribution of the mean coverage from all PCAWG 
matched-normal samples (N=2,834) analyzed shows a mean coverage of 30 reads per genome. Violin plot features are as in ‘a’. (d) 
Matched-normal samples mean depth of coverage distribution by cancer type. Number of samples per tumour type is shown in 




Supplementary Figure 2 
Distribution of somatic retrotranspositions according to subfamily. 
(a) L1 subfamilies. Ta-1 and Ta-0 elements – the youngest subfamilies of L1 retrotransposons – represent 97.5% of all L1 somatic 
mobilizations that were characterized to subfamily level, although we also find 367 L1 events bearing the diagnostic hallmarks of pre-Ta 
elements, which have been shown to retain retrotransposition activity in modern humans
5
. The category “Ta-?” contains those L1-Ta 





Supplementary Figure 3 
Overview of TraFiC-mem. 
TraFiC-mem analyzes Illumina paired-end mapping data (see Supplementary Note).  i) Identification of candidate somatic mobile 
element insertions (MEIs) by TraFiC-mem. Solo-retrotransposon insertions are detected by the identification of two reciprocal clusters 
(positive and negative, or head-to-head) of interchromosomal reads whose mates map onto retrotransposons of the same type located 
elsewhere in the genome. Partnered transductions are detected by the identification of one cluster of interchromosomal reads whose 
mates map onto L1 retrotransposons of the same family elsewhere in the genome, and one single reciprocal cluster of reads whose 
mates are clusterered at a unique region adjacent to a donor source L1 element (the example illustrates a transduction from 
chromosome 7). Orphan transductions are detected by the identification of two reciprocal clusters whose mates map downstream to a 
source element as described for partnered transductions. ii) MEI breakpoint analysis. TraFiC-mem seeks for two additional clusters (5’ 
 
 
brakpoint cluster and 3’ breakpoint cluster) of clipped reads in the candidate insertion region, in order to reveal the 5’ and 3’ insertion 
breakpoint coordinates to base-pair resolution. iii) MEI structural features annotation. iv) Subfamily assignment. Subfamily specific 
diagnostic nucleotides are used to determine the subfamily for L1 events. v) MEI locus annotation: The target genomic region is 





Supplementary Figure 4 
Validation and evaluation of TraFiC-mem. 
(a) Retrotransposition breakpoint validation approach using long-reads with Oxford Nanopore Technologies (ONT). Illustrative example 
of a Solo-L1 insertion in cancer cell-line NCI-H2087 detected with short and long-reads. Top, TraFiC-mem relies on the identification of 
discordant read-pairs (DPs) and clipped reads (CRs) to detect a Solo-L1 insertion using Illumina paired-end data. Bottom, indel reads 
(IRs) and clipped reads confirmation using ONT. (b) For each type of insertion (solo-L1, partnered transductions, orphan transductions, 
Alu), the proportion of events that are supported by different counts of long-reads is represented (from zero to more than 5 reads). 
Events supported by at least one long-read and absent in the matched-normal sample were considered true positive (i.e., somatic), 
while those not supported by ONT and/or present in the matched-normal sample were considered false positive. The total number of 
events assessed for each retrotransposition category is shown in parenthesis. (c) Precision and recall of TraFiC-mem after in-silico 
simulation of 10,000 L1 insertions (Solo-L1, partnered and orphan transductions) in tumors of different clonalities at 25%, 50%, 75% 
and 100%. (d) Plot showing the correlation between the observed and expected lengths for 8,025 Solo-L1 insertions simulated in-silico. 
Sample size (N), Spearman's rho and P-value are displayed above the panel. (e) Fraction of true positive Solo-L1 events with a 
predicted orientation consistent (green), and inconsistent (red), with the expected. Orientation consistency was assessed for four 





Supplementary Figure 5 
Rates of somatic retrotransposition across PCAWG tumor types. 
Violin plots showing the distribution of the number of retrotranspositions per sample across cancer types, for the six different categories 
of retrotranspositions that were analyzed (Solo-L1, L1-transductions, L1-mediated deletions, Alu, SVA and Processed pseudogenes). 
The number of samples per tumor type is shown in parenthesis. Y-axis is represented in a logarithmic scale. Black points, median; 





Supplementary Figure 6 
TP53 mutation is associated with high rates of L1 retrotransposition and structural variants. 
(a) Distribution of L1 counts of three sample groups according to their TP53 mutational status: wild-type, monoallelic and biallelic driver 
mutation. The number of samples per group is shown within parenthesis. Point, median; box, 25th to 75th percentile (interquartile 
range, IQR); whiskers, data within 1.5 times the IQR. P-values indicate significance from a two-tailed Mann–Whitney U-test. Y-axis 
is presented in a logarithmic scale. (b) The same for structural variant (SV) counts. (c) Distribution of L1 counts across tumor types from 
samples grouped in two categories: TP53 wild-type and TP53-mutated (monoallelic or biallelic). The number of samples per tumor type 
and TP53 status (green: wild-type; orange: mutated) is shown within parenthesis. Violin plot features are as in ‘a’. Outlier values 
outside 1.5 times the IQR are represented as diamonds. P-values indicate significance from a two-tailed Mann–Whitney U-test. Y-




Supplementary Figure 7 
Correlation between L1 retrotransposition and structural variation burden. 
(a) Heatmap showing the correlation between the number of L1 events, the total number of structural variants (SVs) and the number of 
5 different types of SVs per sample: deletions (DEL), duplications (DUP), translocations (TRANS), head-2-head inversions (H2HINV) 
and tail-2-tail inversions (T2TINV). Correlation was assessed both at Pan-Cancer and tumor type levels. Spearman´s correlation 
coefficients are shown in a blue (negative) to a red (positive) colored gradient. P-values lower than 0.05 and 0.01 are represented as 
single and double asterisks, respectively. (b) Scatter plots showing correlations between the number of L1 events and the total number 
of SVs per sample at both Pan-Cancer and tumour type levels, for those comparisons that were significant in panel ‘a’. The sample size 





Supplementary Figure 8 
Some gene expression effects associated with somatic retrotransposition in PCAWG. 
(a) Volcano plot showing the impact of L1 integration in the expression of cancer genes. Gene expression fold-change (x axis) is 
represented versus inverted significance (y axis). Red dots indicate significant associations under Benjamini–Hochberg adjusted p-
values < 0.1 from two-tailed Student’s t-test. Adjusted p-values for ABL2 and RB1 are 0.0017 and 0.0014, respectively. (b) Up-
regulation of the ABL2 oncogene in tumour SA494343, a head-and-neck squamous carcinoma (Head-SCC), relative to the expression 
of the same oncogene in other Head-SCC samples (blue) from PCAWG. Expression levels measured as Fragments Per Kilobase 
Million (FPKM). (c) Gene expression differences for genes with L1-retrotranspositions in promoter regions reveals significant 
upregulation in four genes. Volcano plot features are as in ‘a’. Adjusted p-values for MTRNR2L1, ESRRG, ABL2 and MAGEA4 are 
1.1294
e-06
, 0.0009, 0.0017 and 6.0019
e-13
, respectively. (d) Exonization of somatic retrotranspositions, including cancer genes PTPN11 
and NCOR2. Green boxes are exons, thinner green blocks UTRs, lines introns and dotted lines means that a piece of the gene model 
is not shown for visualization purposes. Purple and orange boxes correspond to L1 and Alu integrations, respectively.  Discordant read-
pairs supporting fusion transcript expression are shown above the predicted transcript. (e) Host gene and processed pseudogene 
fusion transcripts. Arcs with arrows within the circos indicate the processed pseudogene events, connecting the source gene 
(underlined and bold) with the corresponding integration site. Predicted fusion transcript structures are shown in the outermost layer of 
the figure. Coding potential is shown underneath the fusion transcript representation. Start codon is denoted as ATG, termination codon 





Supplementary Figure 9 
L1 integration and genomic features. 
(a) Correlation between the number of L1 events and L1 endonuclease (EN) motif instances per 1 Mb-windows. The sample size (N) 
together with Spearman's rho and P-value is displayed above the plot. 2D Kernel density estimate (KDE) is displayed over the data 
points in a blue to red gradient. (b) Correlation between the number of somatic L1 insertions per Mb and replication timing, which is 
measured through Repli-seq wavelet-smoothed signal (late to early replication) and averaged per Mb. Plot features are as in ‘a’. (c-e) 
In each panel, enrichment scores are shown, adjusted for multiple covariates and comparing the L1 insertion rate in bins 1-3 for a 
particular genomic feature versus bin 0 of the same feature, which therefore always has log enrichment=0 by definition and is not 
shown. The error bars represent 95% confidence intervals. The number of observations per bin is provided between parenthesis 
whenever possible. For replication time, bin 0 is the latest-replicating quarter of the genome. For essentiality, bin 0 is the non-essential 
genes. For the L1 motif, bin 0 denotes a non-match (4 or more mismatches). MMs stands for the number of mismatches relative to the 
consensus L1 EN motif. Additional information in Supplementary Note. (d) Association between L1 insertion rate and multiple genomic 
features for those tumour types with at least 100 L1 events. Data colored according to tumor type. (e) Association between L1 insertion 






Supplementary Figure 10 
PCR validation of somatic L1-mediated rearrangement calls. 
Gel showing PCR results on cancer cell-lines (NCI-H2009 and NCI-H2087) and their matched-normal cell-lines (NCI-BL2009 and NCI-
BL2087). We performed validation of 20 L1-mediated rearrangements (for details, see Supplementary Table 7): 16 L1-mediated 
deletions (Rg1, Rg2, Rg3, Rg4, Rg6, Rg8, Rg9, Rg10, Rg11, Rg13, Rg14, Rg15, Rg16, Rg17, Rg18, Rg19), 1 L1-mediated 
translocation (Rg20) and 3 independent L1 breakpoints associated with a copy number change from an unknown rearrangement type 
(Rg5, Rg7, Rg12). For each rearrangement, except those where only one breakpoint is known, at least three regions were amplified in 
the tumours (see Online Methods): left breakpoint (L), right breakpoint (R), and the target site (T). Arrows are used to highlight the 
position of some somatic amplicons. Note that the target site could also amplify in the matched-normal sample if the deletion is not too 
long. “M” denotes the size marker. For illustrative purposes, the oligo design strategy is shown in a panel at the bottom of the figure: 
amplicons (L, R and T) and oligos – forward (F) and reverese (R) – are represented. This experiment was repeated 3 times with the 






Supplementary Figure 11 
Single-molecule sequencing validation of somatic L1-mediated rearrangement calls. 
We sequenced to high-coverage (>1,000x) the PCR amplicons shown in Supplementary Fig. 10 using single-molecule sequencing with 
a MinION sequencer (Oxford Nanopore Technologies). We also carried out whole-genome single-molecule sequencing to low coverage 
of the same two tumor cell-lines (NCI-H2009 and NCI-H2087) subjected to PCR validation. For illustrative purposes, this figure only 
shows the validation of four representative rearrangements (Rg18, Rg11, Rg13, Rg20). The sequences of the remaining PCR 
amplicons can be found in Supplementary Table 7. On the left side of each panel, paired-end and Oxford Nanopore reads supporting a 
given rearrangement are displayed over a virtual reconstruction of the rearrangement breakpoints. On the right side of each panel, 
nucleotide sequence obtained by single-molecule sequencing validating each event shown in left. Nucleotide colors match those in the 
virtual reconstruction of the rearrangement (blue for L1, bright-green for poly-A, grey for target region, light-green for transduction). (a) 
Solo-L1 insertion mediating a 642 bp deletion. (b) Partnered transduction promoting a 2.6 Kb long deletion. (c) A 1.5 Kb deletion 
generated through an endonuclease independent L1 integration. Long reads confirm the truncation of the L1 element at its 5′ and 3′ 
ends. (d) Translocation between 1q31.1 and 8q24.12 mediated by an orphan transduction (same rearrangement as in Fig. 6b). 





Supplementary Figure 12 
Validation of L1-mediated rearrangements in cancer cell lines by mate-pairs sequencing. 
In order to further validate L1-mediated deletions, we performed mate-pair sequencing of long-inserts libraries (3 kb and 10 kb) on two 
cancer cell-lines with high-retrotransposition rates. In these samples, our algorithms confirmed 16 events with the hallmarks of L1-
mediated deletions, in which the mate-pair data confirmed a single L1-derived (i.e., solo-L1 or L1-transduction) retrotransposition as the 
cause of the copy number loss, and identified the sizes of the deletion and the associated insertion. For illustrative purposes, here it is 
shown the validation of a 10.4 kb long deletion promoted by integration of a 768 bp L1 insertion in the cancer cell-line NCI-H2009. The 
L1 element inserted within the deletion breakpoints is too long to be characterized using standard paired-end sequencing libraries, but 





Supplementary Figure 13 
Some L1-mediated deletions are transduction-competent. 
(a) Circos plot summarizing the three concatenated retrotransposition events shown in the panel b. First event, an L1 transduction 
mobilized from chromosome 7 is integrated into chromosome 9. Second event, this insertion concomitantly causes a 5.3 Mb deletion in 
the acceptor chromosome 9. Third event, the L1 element causing the deletion is subsequently able to promote a transduction that 
integrates into chromosome X. (b) Discordant read-pairs in chromosome 9 supports a 5.3 Mb deletion generated by the integration of a 
transduction from chromosome 7, and reveals an L1-event with full-length structure. Five kilobases downstream, a positive cluster of 




Supplementary Figure 14 
Somatic integration of L1 and telomere loss. 
The PCAWG-11 consensus total copy number and the copy number of the minor allele are plotted as gold and gray bands, 
respectively. (a) In a head-and-neck tumor, SA494271, deletion of 1.9 Mb at the short arm of chromosome 10, which involves the 
telomeric region, is associated with the somatic integration of an L1 retrotransposon. (b) In another head-and-neck tumor, SA494351, 
two independent L1 events promote deletion of both ends of chromosome 5. (c) In a Lung squamous carcinoma, SA503541, the 
aberrant integration of an L1 event bearing 5’ and 3’ transductions causes a complex rearrangement with loss of 50.5 Mb from the long 
arm of chromosome 11 that includes the telomere. Only the two clusters supporting both extremes of a putative L1-mediated fold-back 
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1. ANALYSIS OF SOMATIC RETROTRANSPOSITION 
1.1. Detection of mobile element insertions using TraFiC-mem 
BAM files from tumour and matched-normal pairs were processed with TraFiC-mem 
v1.1.0 (https://gitlab.com/mobilegenomes/TraFiC) to identify somatic mobile element 
insertions (MEIs) including solo-L1, L1-mediated transductions, Alu, SVA and ERV-
K, using Illumina paired-end mapping data. In donors where multiple samples of 
primary, metastatic and/or recurrent tumours were available, each sample was 
independently processed and a list of non-redundant MEI calls for each donor was 
generated by merging the MEI calls from multiple samples as follows: those MEIs 
within a breakpoint offset of ±15 bp were clustered together, and the call supported by 
the highest number of discordant read-pairs in each cluster was selected as 
representative in the merging process.  
 
TraFiC-mem starts by identifying candidate somatic MEIs via the analysis of 
discordant read-pairs. Contrary to previous version of the algorithm 1 , the new pipeline 
uses BWA-mem instead of RepeatMasker as search engine for the identification of 
retrotransposon-like sequences in the sequencing reads. Calls obtained at this step are 
preliminary, in which MEI features are outlined and insertion coordinates represent 
ranges surrounding the breakpoints. Then, a new module of TraFiC-mem, called 
MEIBA (from Mobile Element Insertion Breakpoint Analyzer) 
(https://github.com/brguez/MEIBA/tree/master/src/python), is used to identify the 
integration breakpoints to base-pair resolution, and to perform a detailed 
characterization of MEI features, including structure, subfamily assignment, and 
insertion site annotation. TraFiC-mem is illustrated in Supplementary Fig. 3. 
 
1.1.1. Identification of MEI candidates via discordant reads analysis 
- Identification of Solo-element events: TraFic-mem identifies reads from 
BWA-mem mapping that are likely to provide information pertaining to mobile 
elements site inclusion. Two different read-pair types are considered for the 
identification of insertions, named INTER_CHROM (each end of the pair are mapped 
to different chromosomes, where the end with the highest mapping quality (MAPQ) is 
considered the anchor in the reference genome), and ABERRANT (both ends of the 
pair are impropertly mapped to the same chromosome, where the end with the highest 
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MAPQ is considered the anchor). In all cases the anchor end must have a MAPQ higher 
than zero. The pair is excluded if any of the reads is not a primary alignment, fails 
platform/vendor quality checks, or is PCR or optical duplicate. Then, all non-anchor 
reads with an anchored mate MAPQ > 0 are interrogated for the existence of mobile 
element-like sequences. At this step, non-anchor reads are realigned with BWA-mem 
v0.7.171 into a database containing a set of human full-length mobile element consensus 
sequences, including L1, Alu, SVA and ERV-K. After BWA-mem search, all anchored 
reads with mates containing sequences from the same mobile element type are clustered 
together if (a) they have the same orientation – positive or negative – and (b) the 
distance relative to the nearest mapped read of the same cluster is equal or less than the 
average read size. Two main cluster categories are considered, namely positive and 
negative clusters (i.e., anchor reads mapped onto the reference genome with positive 
and negative orientation, respectively). Initially, a range of genome coordinates is 
associated with each single cluster (breakpoint coordinates are refined in a later step – 
see “Reconstruction of MEI breakpoints via clipped-reads analysis”). Ranges are 
conformed by a lower coordinate (P_L_POS and N_L_POS, respectively for positive 
and negative clusters) and an upper coordinate (P_R_POS and N_R_POS, for positive 
and negative). One positive and one negative cluster are reciprocal if P_R_POS ≥ 
N_L_POS and abs(N_L_POS – P_R_POS) ≤ 2(average read size). Only positive and 
negative clusters conformed of 4 or more reads are employed in the assignment of 
reciprocal clusters. Each reciprocal cluster identifies a candidate mobile element 
insertion (Supplementary Fig. 3a). 
 
- Identification of L1 transductions: Two types of L1-mediated transductions 
were identified 1, namely partnered transductions, in which an L1 and downstream 
nonrepetitive sequence are retrotransposed together, and orphan transductions, in which 
only the unique sequence downstream of an active L1 is retrotransposed without the 
cognate L1. As above, two different read-pair types, INTERCHROM and ABERRANT 
are considered. In all cases the anchor read and the corresponding mate must have a 
MAPQ ≥ 37. Then, anchored reads are clustered together if (a) they share the same 
orientation, (b) the distance relative to the nearest mapped read of the cluster is equal 
or less than the average read size, and (c) their mates are also clustered together. Two 
main cluster categories are considered, namely positive and negative clusters, as above. 
The integration breakpoint of a potential partnered transduction is defined by reciprocal 
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clusters conformed of one-single cluster of (a) INTER_CHROM and/or ABERRANT 
reads that support an L1 and (b) one-single cluster of INTER_CHROM and/or 
ABERRANT reads that supports the integration of a unique DNA region from 
elsewhere in the genome that is located downstream to an L1 source element locus. One 
L1 cluster and one INTER_CHROM and/or ABERRANT cluster are reciprocal if they 
are in opposite orientation and P_R_POS ≥ N_L_POS and abs(N_L_POS – P_R_POS) 
≤ 2(average read size). Only positive and negative clusters conformed of 4 or more 
reads are employed in the assignment of reciprocal clusters. Reciprocal clusters 
represent preliminary transduction calls that must pass the filters described below to be 
finally selected. The integration breakpoint of a potential orphan transduction is defined 
by two reciprocal clusters conformed of INTER_CHROM and/or ABERRANT reads. 
In this case, two clusters of INTER_CHROM and/or ABERRANT reads are reciprocal 
if (a) they are in opposite orientation, (b) P_R_POS ≥ N_L_POS and abs(N_L_POS – 
P_R_POS) ≤ 2(average read size), and (c) the two single clusters that constitute their 
mates are mapped within a distance of 10 kb to each other (Supplementary Fig. 3a). 
 
TraFiC-mem performs the actions described above in both, the tumour and the matched 
normal genomes. In order to remove potential germline calls, MEI candidates are 
filtered out from the tumour sample if: (a) they are located within 200 bp of a cluster 
from the same retrotransposon family in the matched normal sample that is supported 
by at least 3 reads; and/or (b) there is a polymorphic insertion from the same 
retrotransposon family within a range of 200 bp that is present in ‘TraFiC-ip db’ 1 , 
dbRIP 2, the 1,000 Genomes Project Phase 3 callset 3,4 or the dataset of germline events 
identified by our group across PCAWG5. Finally, we noticed the existence of mapping 
artefacts leading to quite frequent false positive insertion calls (particularly in Alu and 
SVA calls), located within or between repeats of the same family in the reference 
genome. So, an additional filter is applied to remove those insertions located within a 
range of ±150 bp of an element from the same family that shows ≥85% of nucleotide 
identity relative to the consensus sequence of the family. 
 
1.1.2. Reconstruction of MEI breakpoints via clipped-reads analysis 
A new module of TraFiC-mem, called MEIBA, is used to identify the breakpoints of 
an insertion to base-pair resolution. The algorithm uses two classes of reads mapped 
	 6	
with BWA-mem, namely soft and hard clipped reads, which overlap a putative insertion 
breakpoint. These reads consist of two segments, one that aligns onto the insertion 
target region and a second that aligns onto a mobile element elsewhere in the reference 
genome. Thus, once MEI candidates have been identified, TraFic-mem seeks for two 
additional clusters of clipped reads (CRs) that would indicate the exact insertion 
breakpoint coordinates (each individual insertion has two breakpoints, namely 5’ and 
3’ breakpoints). Soft and hard CRs are extracted within a range of ±50 bp to the positive 
cluster P_R_POS cordinate identified in step “i” of the pipeline via discordant read-
pairs. Reads marked as duplicates and reads clipped both at the beginning and ending 
extremes are filtered out, as they usually constitute mapping artefacts. The same 
approach is applied to the negative cluster N_L_POS coordinate of the same putative 
MEI, and both sets of reads, belonging to positive and negative clusters, are merged 
into a non-redundant dataset as follows: CRs are organized into clusters supporting the 
same breakpoint position using a maximum breakpoint offset of 3 bp. Those clusters in 
the tumour that are also detected in the matched-normal genome, and/or those clusters 
with an overrepresentation of CRs overlapping the breakpoint (we used a cut-off of 
more than 500 CRs), are excluded. Then, for each breakpoint cluster, supporting CRs 
are submitted to multiple sequence alignment using MUSCLE v3.8.31 6, and a 
consensus sequence spanning the insertion breakpoints is constructed with “Cons” from 
the EMBOSS suit v6.6.0 7. The consensus sequences obtained are processed to assess 
if they span the target genome region and mobile element breakpoint junction (5’ 
breakpoint), or the target region and poly(A) tail junction (3’ breakpoint). If more than 
one 5’ and/or 3’ breakpoints are generated, the one supported by the highest number of 
CRs is selected. Finally, insertion breakpoints are required to be consistetly supported 
by at least two CRs, and candidate MEIs are filtered out if they do not have at least one 
of the two insertion breakpoints characterized to base pair resolution. 
 
1.1.3. MEI structural features annotation 
MEI structural features including insertion length, structure condition (full-length, 
partial, inverted), orientation, and size of target site duplication (TSD) or target site 
deletion, are determined for the insertions with both breakpoints successfully 
reconstructed. In order to compute the insertion size, the consensus sequence spanning 
the 5’ breakpoint is realigned to the corresponding L1, Alu, SVA or ERV-K reference 
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sequence using Blat v34.0 8. Next, as retrotransposons usually only get truncated at 
their 5’-extreme, the insertion length is computed as the distance between the beginning 
of the alignment and the end of the reference sequence. Insertions spanning less than 
98% of the consensus sequence for each family of retrotransposons are considered 5’-
truncated, and/or if the sequence aligns in opposite orientation than the insertion DNA 
strand are considered 5’-inverted; otherwise, insertions are catalogued as full-length. 
MEIs with positive orientation are supported by clusters at the 5’ and 3’ breakpoints 
whose CRs are clipped at their ending (end-clipped) and their beginning (beg-clipped), 
respectively; while MEIs with negative orientation show the opposite clipping pattern. 
TSD and target-site deletion sizes are estimated as the distance between the two 
insertion breakpoints. Insertions with TSD show a breakpoint coordinate supported by 
the end-clipped cluster that is higher than the breakpoint coordinate supported by the 
beg-clipped cluster. Target site deletions show the opposite pattern. 
 
1.1.4. MEI subfamily assignment 
Two different strategies are applied to infer the subfamily of the inserted L1, Alu, SVA 
and ERV-K element. For L1 insertions, discordant read-pairs from supporting 
reciprocal clusters are realigned onto an L1 consensus sequence (GenBank identifier: 
L19088.1) using BWA-mem v0.7.17. The resulting SAM is converted into a binary 
sorted BAM file using samtools v1.7 9. Then, genotype likelihoods at each genomic 
position are computed with samtools mpileup, reference and variant sites are called 
with bcftools v1.7 consensus caller 10 and filtered requesting a quality score higher than 
20 and a minimum read depth of 2. Finally, subfamily inference is done based on the 
identification of subfamily diagnostic nucleotide positions 11: L1 integrations bearing 
the diagnostic “ACG” or “ACA” triplet at 5,929-5,931 position are classified as “pre-
Ta” and “Ta”, respectively. Ta elements are subclassified into “Ta-0” or “Ta-1” 
according to diagnostic bases at 5,535 and 5,538 positions (Ta-0: G and C; Ta-1: T and 
G). When sequencing reads do not cover the diagnostic nucleotides, subfamily cannot 
be inferred. For Alu, SVA and ERV-K, discordant read-pairs from reciprocal clusters 
supporting the insertions are assembled with velvet v1.2.10 12, using a k-mer length of 
21 bp, and the resulting contig is processed with RepeatMasker v4.0.7 to determine the 
subfamily. If multiple RepeatMasker hits are obtained, the one with the highest Smith-
Waterman score is selected as representative. MEIs will be discarded if preliminary 
family assigment in “i” and subfamily assigment are not consistent. 
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1.1.5. MEI locus annotation 
The target genomic region is annotated using the software ANNOVAR v2016-02-01 13 
and GENCODE v19 basic annotation 14. MEIs inserted within cancer genes, according 
to the Cancer Gene Census COSMIC database v77 15, are flagged.  
 
1.1.6. TraFiC-mem output 
The primary TraFiC-mem output is a standard Variant Call Format (VCF) v4.2 file 
containing all somatic MEI calls coordiantes with annotation features, including family, 
subfamily, insertion length, structural condition, orientation, size of TSD or deletion, 
gene annotation, number of supporting reads, and consensus sequences spanning the 
breakpoint junctions. Additional information is provided for L1-mediated 
transductions, which includes the transduced sequence length, the genomic position of 
the source element, and source element. MEI candidates that were filtered out are also 
reported together with filtering reasons. 
 
1.1.7. TraFiC-mem availability and distribution 
TraFiC-mem is implemented using Snakemake 16, a flexible Python-based workflow 
language, that allows to execute the pipeline from single-core workstations to 
computing clusters, without the need to modify the workflow. In order to enhance 
reproducible research, TraFiC-mem and its third party dependencies are also distributed 
as a Docker image (https://hub.docker.com/r/mobilegenomes/trafic). TraFiC-mem is 




1.2. Identification of L1-mediated deletions 
Independent read clusters, identified with TraFic-mem, supporting an L1 event (i.e., 
clusters of discordant read-pairs with no apparent reciprocal cluster within the proximal 
500 bp, and whose mates support a somatic L1 retrotransposition event) were 
interrogated for the presence of an associated copy number change in its proximity. 
Briefly, we looked for copy number loss calls from PCAWG-11 (see “Copy number 
dataset” above) for which the following conditions were fulfilled: (i) the upstream 
breakpoint matches an independent L1 cluster in positive orientation, (ii) the 
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corresponding downstream breakpoint, if any, from the same copy number change 
matches an independent L1 cluster in negative orientation, and (iii) the reconstruction 
of the structure of the putative insertion causing the deletion is compatible with one-
single retrotransposition event. We used MEIBA – described above – to reconstruct the 
insertion breakpoint junctions in order to confirm the ends of the events and identify 
hallmarks of retrotransposition, including the poly(A) tract and duplication of the target 
site. 
 
Further to the strategy described above, an additional strategy was adopted to identify 
L1-mediated deletions shorter than 100 kb, as follows. Coverage drops in the proximity 
of each independent cluster were detected by, first, normalizing read depth on each side 
of the cluster using the matched normal sample as a reference. Then, the ratio between 
the normalized read depth on both sides of the cluster was computed. This calculation 
was performed for window sizes ranging between 200 and 5,000 bp, with the windows 
on both sides of the cluster always having the same length. An immediately adjacent 
‘buffer’ region of 300 bp was defined on each side of the cluster, and reads within these 
regions were omitted in read depth calculations, in order to prevent false positives due 
to sequence repeats at the cluster location. Subsequently, pairs of independent 
reciprocal (positive–negative) clusters were selected for which (i) the two clusters were 
located less than 100 kb apart, (ii) a potential drop in read depth ratio was identified, 
extending from the positive cluster to the negative cluster (statistical significance of 
read depth ratios was estimated non-parametrically, as described below), and (iii) the 
reconstruction of the structure of the putative insertion causing the deletion was 
compatible with a single L1 event. For each selected cluster pair, the continuity and 
reliability of the copy number drop was assessed by measuring the normalized read 
depth ratio between non-overlapping 500 bp windows spanning the region between the 
positive and negative clusters (i.e. within the putative deletion) and windows located 
upstream and downstream of the positive and negative cluster (i.e. outside the putative 
deletion), respectively. The significance of each drop in read depth ratio was estimated 
non-parametrically using a null distribution of normalized read depth ratios. This 
distribution was obtained for each tumour sample by randomly sampling 100,000 
genomic locations, drawn from the copy number segments with the predominant copy 
number in that particular sample (If the predominant copy number was 1, then segments 
with a copy number of 2 were used instead to avoid extreme read depth ratios that could 
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arise from potentially undetected deletions). Specifically, read depth ratios were 
calculated from this sample of locations by comparing the normalized read depth 
between two 2,500-bp windows located immediately upstream and downstream of each 
location. Non-parametric p-values were calculated by comparing the observed read 
depth ratios with the ones in this null distribution, and adjusted via Benjamini–
Hochberg (BH) multiple-testing correction. Three groups of output clusters were 
produced, corresponding to decreasing significance of the candidate deletions: first, 
pairs of reciprocal clusters where both clusters present an adjusted p-value below 0.1 
(‘Tier 1’ candidates); second, pairs of reciprocal clusters where only one cluster 
presents an adjusted p-value below 0.1 (‘Tier 2’ candidates); and third, any individual 
clusters presenting an adjusted p-value below 0.1 (‘Tier 3’ candidates). The resulting 
L1-mediated deletion candidates (Tiers 1 and 2) were subsequently confirmed via 
visual inspection using the Integrative Genomics Viewer (igv) 17. 
 
1.3. Analysis of the association between L1 insertion rate and genomic features 
L1 insertion rate was calculated as the total number of somatic L1 insertions, identified 
across the complete PCAWG cohort, per 1-Mb window. L1 endonuclease motif density 
was computed as the number of canonical endonuclease motifs, here defined as TTTT|R 
(where R is A or G) or Y|AAAA (where Y is C or T), per 1-Mb. Bivariate correlations 
between L1 insertion rate, endonuclease motif density and replication timing were 
assessed using Spearman’s rank. 
 
To study  the  association of L1 insertion rate with multiple  predictor  variables at 
single-nucleotide resolution we used a statistical framework based on negative 
binomial regression, as described in detail previously 18. This method was adapted 
herein such that originally the regression adjusted for content of trinucleotides in each 
genomic bin, while in this case we instead adjusted for the content of the L1 
endonuclease motif. More specifically, we stratified the genome into four bins (0-3) by 
the closeness of match to the canonical L1 motif, here defined as TTTT|R (where R is 
A or G). The bin 0 contains dissimilar DNA motifs, which have 4 or more (out of 5) 
mismatches (MMs), encompassing 1149.7 Mb of the genome. Bin 1, 2 and 3 contain 
genome segments with exactly 3, exactly 2 and at most 1 MM, encompassing 749.4 
Mb, 380.2 Mb and 114.1 Mb of the GRCh37 assembly, respectively. The closest match 
of either of the two DNA strands was considered. 
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Histone mark data (ChIP-Seq for H3K9me3, H3K4me3, H3K36me3, H3K27ac) and 
DNase hypersensitivity (DHS) data for the regional analyses was collected from 
Roadmap Epigenomics Consortium by averaging fold-enrichment signal over 8 cell 
types (E017, E114, E117, E118, E119, E122, E125 and E127) and processed by 
stratifying into four genomic bins, as described previously 18. For histone marks and 
DHS, bin 0 are the areas of the genome with below-baseline signal (Roadmap fold-
enrichment compared to input < 1), while bins 1-3 are approximately equal-sized bins 
covering the remaining parts of the genome with above-average fold-enrichment score. 
In particular, DHS bins 1-3 encompass 122.8-123.0 Mb each; for H3K36me3 129.1-
136.0 Mb each; for H3K4me3 43.2-43.7 Mb each; for H3K27ac 73.6-75.1 Mb each. 
RNA-Seq data was also collected from Roadmap and processed as previously 18 by 
averaging over 8 cell types (E071, E096, E114, E117, E118, E119, E122, E127): bin 0 
consisted of non-expressed genes (FPKM=0) and intergenic DNA that was not 
explicitly listed as expressed (total 1076.6 Mb), while bin 1 (up to 0.59 FPKM), 2 (up 
to 5.68 FPKM) and 3 (above 5.68 FPKM) spanned 389.9, 462.1 and 473.8 Mb of the 
genome, respectively. Replication time (RT) data was processed similarly as histone 
marks, but collected from ENCODE and processed by averaging the wavelet-smoothed 
signal over 8 cell types (HeLa S3, HEP G2, HUVEC, NHEK, BJ, IMR-90, MCF-7 and 
SK-N-SH) and then dividing into four equal-sized genomic bins (quartiles), where bin 
0 is the latest-replicating and bin 3 is the earliest replicating. Essential genes were 
determined by CERES score based on CRISPR essentiality screens, ordering by median 
score across all 342 cell lines tested 19  and then stratifying genes into equal-frequency 
bins, from less negative to more negative median CERES score (implying commonly 
essential genes). For the purposes of finding L1 rates in CERES essential genes an 
additional 1 kb flanking the transcript was also considered together with the gene. All 
enrichment scores shown in plots compare bins 1-3 for a particular feature (RT, histone 
marks, gene expression, L1 motif) versus bin 0 of the same feature, which therefore 
always has log enrichment=0 by definition and is not shown on enrichment plots. The 
regional analyses are restricted to parts of the genome with perfect mappability scores, 
according to the CRG Alignability 75 track of the UCSC browser. 
 
Further to what is reported in the main text, our analyses confirm fewer L1 events at 
active promoters (1.63-fold), here detected by the H3K4me3 histone mark 20, yet there 
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is no decrease at active enhancers, marked by H3K27ac; and we detect no significant 
association between gene essentiality and L1 rates (1.03-fold decrease in essential 
genes), suggesting that only a minor fraction of the somatic L1 events may be under 
negative selection (Supplementary Fig. 9c). Different cancer types and different 
samples appear remarkably consistent in the biases of L1 events towards later-
replicating DNA and towards other epigenomic features examined (Supplementary 
Fig. 9d-e) 
 
1.4. Validation of TraFiC-mem calls using single-molecule sequencing 
Due to the unavailability of Pan-Cancer DNA specimens, in order to evaluate our 
algorithm for the identification of retrotransposon integrations, we performed 
validation of 308 putative somatic retrotranspositions identified with TraFiC-mem in 
one cancer cell-line (NCI-H2087) with high retrotransposition rate, and absent in its 
matched normal cell-line (NCI-BL2087) derived from blood, by single-molecule 
sequencing using Oxford Nanopore technology. Genomic DNA was sheared to 10 kb 
fragments using Covaris g-TUBEs (Covaris), cleaned with 0.4x Ampure XP Beads 
(Beckman Coulter Inc). After end-repairing and dA-tailing using the NEBNext End 
Repair/dA-tailing module (NEB), whole-genome libraries were constructed with the 
Oxford Nanopore Sequencing 1D ligation library prep kit (SQK-LSK108, Oxford 
Nanopore Technologies Ltd). We obtained four and five libraries for NCI-H2087 and 
NCI-BL2087, respectively. Genomic libraries were loaded on MinION R9.4 flowcells 
(FLO-MIN106, Oxford Nanopore Technologies Ltd), and sequencing runs were 
controlled using the Oxford Nanopore MinKNOW software v18.01.6. We used the 
Oxford Nanopore basecaller Albacore v2.0.1 to identify DNA sequences directly from 
raw data and generate fatsq files. Files with quality score values below 7 were excluded 
at this point. Minion adapter sequences were trimmed using Porechop v0.2.3 
(https://github.com/rrwick/Porechop). Then, we used minimap2 v2.10-r764-dirty21 to 
map sequencing reads onto the hs37d5 human reference genome, and the SAM files 
were converted to BAM format, sorted and indexed with Samtools v1.7 for each one of 
sequencing runs. BAM files were merged, sorted and indexed. After this process, 
sequencing coverage were 8.2x (NCI-BL2087) and 9.17X (NCI-H2087), and average 
read size of mapped reads were ~4.5 kb (NCI-BL2087) and ~11 kb (NCI-H2087). 
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Once having the whole-genome BAM files, for each one of the 308 putative somatic 
retrotransposition call identified with TraFic-mem, we interrogated the long-read 
tumour BAM file to seek for reads validating the event. Two types of MEI supporting 
clusters of sequencing reads were catalogued (Supplementary Fig. 4a), namely (i) 
“indel-read clusters”, composed of Nanopore-reads completely spanning the insertion, 
so they can be identified as a standard insertion on the reference, and (ii) “clipped-read 
clusters”, composed of Nanopore-reads spanning only one of the inserted element 
extremes, so they get clipped during the alignment in the reference. We observe that 
short MEI insertions are predominantly supported by indel-read clusters, while longer 
MEI insertions are mainly supported by clipped-read clusters. MEIs supported by at 
least one Nanopore-read in the tumour and absent in the matched-normal sample were 
considered true positive (TP) somatic events, while MEIs not supported by long-reads 
in the tumour and/or present in the matched-normal were considered false positive (FP) 
calls. Overall, we find 4.22% (13/308) false positive events, which showed to be 
particularly frequent in regions with low sequencing coverage. However, we cannot not 
rule out the possibility that these are true positive events, as they were not found in the 
matched-normal sample. False discovery rate (FDR) was estimated as follows: FDR = 
FP / (TP + FP). 
 
1.5. Validation of L1-mediated rearrangements with PCR and single-molecule 
sequencing 
Due to the unavailability of Pan-Cancer DNA specimens, we performed validation of 
20 somatic L1-mediated rearrangements, mostly deletions, identified in two cancer 
cell-lines with high retrotransposition rates (NCI-H2009 and NCI-H2087). We carried 
out PCR followed by single-molecule sequencing of amplicons from the two tumour 
cell-lines and their matched normal samples (NCI-BL2009 and NCI-BL2087), using a 
Minion sequencer from Oxford Nanopore. PCR primers were designed with Primer3 
v0.4.0 22 , to amplify three regions from each event (namely, 5’-extreme, 3’-extreme 
and target site) as follows. For the amplification of the 3’-extreme of the event (the one 
that contains the poly(A) tract), we designed one forward oligo to hybridize the 3’ 
extreme of the MEI, and a reverse oligo that hybridizes the DNA downstream. In the 
case of Solo-L1s, we used an L1Hs specific forward oligo matching the 3’-UTR: 5’-
GGGAGATATACCTAATGCTAGATGACAC-3’ 23, or an alternative forward oligo 
that matches other region at the 3’-extreme of the element. For the amplification of the 
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target site in the tumour and matched normal, we designed primers to amplify the DNA 
sequence between both breakpoints (5’ and 3’) of the rearrangement. For the 
amplification of the 5’-extreme of a MEI in a tumour, we designed one forward oligo 
to match the non-repetitive region immediately adjacent to the 5’-extreme of the 
element, and a reverse oligo that hybridizes the 5’ extreme of the MEI. 
 
Each PCR mixture contains 10ng of DNA, 5pmol of each primer, 5U Taq DNA 
polymerase (Sigma-Aldrich, catalog number D1806) with 1x Buffer containing MgCl2, 
0.2mM of each dNTPs, and water to a final volume of 25μl. PCR conditions were as 
follows: initial denaturation at 95ºC for 7 minutes; then 30-35 cycles of 95ºC for 30 
seconds, 60ºC for 30 seconds, 72ºC for 45 seconds; and a final extension of 72ºC for 7 
minutes. In some cases, when amplification was tricky, we used Platinum Taq High-
fidelity, with a 94ºC denaturation and a 68ºC extension. 
 
PCR amplicons were sequenced with single-molecule sequencing using a MinION 
from Oxford Nanopore. Amplicons were pooled and total DNA was cleaned with 0.4x 
AMPure XP Beads (Beckman Coulter Inc). After end-repairing and dA-tailing using 
the NEBNext End Repair/dA-tailing module (NEB), the sequencing library was 
constructed with the Oxford Nanopore Sequencing 1D ligation library prep kit (SQK-
LSK108, Oxford Nanopore Technologies Ltd) and loaded on a MinION R9.4 flowcell 
(FLO-MIN106, Oxford Nanopore Technologies Ltd). Mapping to human reference 
genome was performed as described above, with minor modifications. 
 
 
2. INTERPRETATION OF THE PAIRED-END MAPPING DATA FROM 
FIGURES 
TraFiC-mem analyzes Illumina paired-end whole-genome sequencing data, aligned 
with BWA-mem, from a pair of tumour and matched-normal samples, to identify 
somatically acquired mobile element insertions (MEIs). All figures in this paper use 
default read colours by Integrative Genomics Viewer (igv)17, where paired-end reads 
are coloured by the chromosome on which their mates can be found. Thus, 
retrotransposon-specific clusters (i.e., clusters of reads supporting the integration of a 
retrotransposon) are conformed of multicoloured reads, because mates can map 
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ambiguously elsewhere in the reference genome where a retrotransposon of the same 
family is present. 
 
Supplementary Fig. 3 illustrates how TraFiC-mem identifies different types of 
candidate somatic MEIs. Briefly, the integration of a Solo-retrotransposon is detected 
by the identification of two reciprocal clusters (positive and negative) of 
interchromosomal (multicoloured) reads whose mates map onto retrotransposon of the 
same type located elsewhere in the genome. The integration of a partnered transduction 
from chromosome 7 is detected by the identification of two different types of reciprocal 
clusters: one cluster of multicoloured interchromosomal reads whose mates map onto 
L1 retrotransposons of the same family elsewhere in the genome, and one single-
coloured cluster of reads whose mates are clustered at a unique region adjacent to a 
donor source L1 element – for illustrative purposes, this last cluster identifies a 
transduction from chromosome 7, and reads from this cluster are homogeneously 
coloured in light-blue because that is the default colour in igv for chromosome 7 –. The 
integration of an orphan transduction from chromosome 7 is detected by the 
identification of two reciprocal clusters of the same type, but this time both clusters are 
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Hongtu Zhu​372,373 
 
PCAWG Portals and Visualization Working Group 
Fatima Al-Shahrour​343​, Elisabet Barrera​7​, Wojciech Bazant​7​, Alvis Brazma​7​, Isidro 
Cortés-Ciriano​223,224,225​, Brian Craft​12​, David Craft​3,226​, Vincent Ferretti​44,65​, Nuno A Fonseca​7,66​, 
Anja Füllgrabe​7​, Mary J Goldman​12​, ​David Haussler​#​12,374​, Wolfgang Huber​8​, Maria Keays​7​, 
Alfonso Muñoz​7​, Brian D O'Connor​44,95​, Irene Papatheodorou​7​, Robert Petryszak​7​, Elena 
Piñeiro-Yáñez​343​, Alfonso Valencia​45,105​, ​Miguel Vazquez​#​45,106​, John N Weinstein​375,376​, Qian 
Xiang​44​, Junjun Zhang​44​ and ​Jingchun Zhu​#​12 
 
PCAWG Mitochondrial Genome and Immunogenomics Working 
Group 
Peter J Campbell​1,2​, Yiwen Chen​140​, Chad J Creighton​227​, Li Ding​130,131,138​, Akihiro Fujimoto​47​, 
Masashi Fujita ​47​, Gad Getz​3,4,5,6​, Leng Han​217​, Takanori Hasegawa​83​, Shuto Hayashi​83​, Seiya 
Imoto​83​, Young Seok Ju​1,172​, Hyung-Lae Kim​27​, Youngwook Kim​91,92​, Youngil Koh​291,292​, Mitsuhiro 
Komura​83​, Jun Li​140​, ​Han Liang​#​140​, Iñigo Martincorena​1​, Satoru Miyano​83​, Shinichi Mizuno​377​, 
Hidewaki Nakagawa ​#​47​, Keunchil Park​192,193​, Eigo Shimizu​83​, Yumeng Wang​140​, John N 
Weinstein​375,376​, Yanxun Xu​378​, Rui Yamaguchi​83​, Fan Yang​368​, Yang Yang​217​, Christopher J Yoon​172​, 
Sung-Soo Yoon​292​, Yuan Yuan​140​, Fan Zhang​232​ and Zemin Zhang​232,255 
 
PCAWG Pathogens Working Group 
Malik Alawi​379,380​, Ivan Borozan​9​, Daniel S Brewer​381,382​, Colin S Cooper​382,383,384​, Nikita Desai​44​, 
Roland Eils​50,52,63,64​, Vincent Ferretti​44,65​, Adam Grundhoff​380,385​, Murat Iskar​386​, Kortine 
Kleinheinz​50,52​, ​Peter Lichter​#​77,386​, Hidewaki Nakagawa​47​, Akinyemi I Ojesina​240,241,242​, Chandra 
Sekhar Pedamallu​3,6,163​, Matthias Schlesner​50,102​, Xiaoping Su​352​ and ​Marc Zapatka​#​386 
 
Providers of tumour-sequencing data 
PCAWG Tumour-specific providers (ovarian cancer) in Australia 
Kathryn Alsop​178​, Australian Ovarian Cancer Study Group​295,387,388​, ​David D L Bowtell​#​178​, Timothy 
JC Bruxner​176​, Angelika N Christ​176​, Elizabeth L Christie​178​, Stephen M Cordner​389​, Prue A 
Cowin​387​, Ronny Drapkin​390​, Dariush Etemadmoghadam​178​, Sian Fereday​178​, Dale W Garsed​178​, 
Joshy George​160​, Sean M Grimmond​348​, Anne Hamilton​387​, Oliver Holmes​295,296​, Jillian A Hung​391​, 
Karin S Kassahn​176,392​, Stephen H Kazakoff​295,296​, Catherine J Kennedy​391,393​, Conrad R 
Leonard​295,296​, Linda Mileshkin​178​, David K Miller​176,345​, Gisela Mir Arnau​387​, Chris Mitchell​178​, 
Felicity Newell​295,296​, Katia Nones​295,296​, Ann-Marie Patch​295,296​, John V Pearson​295,296​, Michael C 
Quinn​295,296​, Mark Shackleton​178​, Darrin F Taylor​176​, Heather Thorne​178​, Nadia Traficante​178​, 
Ravikiran Vedururu​387​, Nick M Waddell​296​, Nicola Waddell​295,296​, Paul M Waring​394​, Scott 
Wood​295,296​, Qinying Xu​295,296​ and Anna deFazio​391,393,395 
 
PCAWG Tumour-specific providers (pancreatic cancer) in Australia 
Matthew J Anderson​176​, Davide Antonello​396​, Andrew P Barbour​397,398​, Claudio Bassi​396​, Samantha 
Bersani​399​, ​Andrew V Biankin​#​222,345,346,347​, Timothy JC Bruxner​176​, Ivana Cataldo​399,400​, David K 
Chang​222,345​, Lorraine A Chantrill​345,401​, Yoke-Eng Chiew​391,393​, Angela Chou​345,393​, Angelika N 
Christ​176​, Sara Cingarlini​36​, Nicole Cloonan​402​, Vincenzo Corbo​400,403​, Maria Vittoria Davi​404​, Fraser 
R Duthie​222,405​, J Lynn Fink​45,176​, Anthony J Gill​345,406​, Janet S Graham​222,407​, ​Sean M Grimmond​#​348​, 
Ivon Harliwong​176​, Oliver Holmes​295,296​, Nigel B Jamieson​222,347,408​, Amber L Johns​345​, Karin S 
Kassahn ​176,392​, Stephen H Kazakoff​295,296​, James G Kench​345,406,409​, Luca Landoni​396​, Rita T Lawlor​400​, 
Conrad R Leonard​295,296​, Andrea Mafficini​400​, Neil D Merrett​396,410​, David K Miller​176,345​, Marco 
Miotto​396​, Elizabeth A Musgrove​222​, Adnan M Nagrial​345​, Felicity Newell​295,296​, Katia Nones​295,296​, 
Karin A Oien​394,411​, Marina Pajic​345​, Ann-Marie Patch​295,296​, John V Pearson​295,296​, Mark Pinese​345​, 
Andreia V Pinho​412​, Michael C Quinn​295,296​, Alan J Robertson​176​, Ilse Rooman​345​, Borislav C 
Rusev​400​, Jaswinder S Samra​396,413​, Maria Scardoni​399​, Christopher J Scarlett​345,414​, Aldo Scarpa​400​, 
Elisabetta Sereni​396​, Katarzyna O Sikora​400​, Michele Simbolo​403​, Morgan L Taschuk​44​, Christopher 
W Toon​345​, Giampaolo Tortora​36,37​, Caterina Vicentini​400​, Nick M Waddell​296​, Nicola Waddell​295,296​, 
Scott Wood​295,296​, Jianmin Wu​345​, Qinying Xu​295,296​ and Nikolajs Zeps​415,416 
 
PCAWG Tumour-specific providers (skin cancer) in Australia 
Lauri A Aaltonen​417​, Andreas Behren​418​, Hazel Burke​419​, Jonathan Cebon​418​, Rebecca A Dagg​420​, 
Ricardo De Paoli-Iseppi​419​, Ken Dutton-Regester​295​, Matthew A Field​421​, Anna Fitzgerald​422​, Sean 
M Grimmond ​348​, ​Nicholas K Hayward​#​295,419​, Peter Hersey​419​, Oliver Holmes​295,296​, Valerie 
Jakrot​419​, Peter A Johansson​295​, Hojabr Kakavand​419​, Stephen H Kazakoff​295,296​, Richard F 
Kefford​423​, Loretta MS Lau​424​, Conrad R Leonard​295,296​, Georgina V Long​419​, ​Graham J 
Mann ​#​393,419,419​, Felicity Newell​295,296​, Katia Nones​295,296​, Ann-Marie Patch​295,296​, John V 
Pearson​295,296​, Hilda A Pickett​424​, Antonia L Pritchard​295​, Gulietta M Pupo​393​, Robyn PM Saw​419​, 
Sarah-Jane Schramm​393​, ​Richard A Scolyer​#​409,413,419​, Mark Shackleton​178​, Catherine A Shang​422​, 
Ping Shang​419​, Andrew J Spillane​419​, Jonathan R Stretch​419​, Varsha Tembe​393​, John F Thompson​419​, 
Ricardo E Vilain​425​, Nick M Waddell​296​, Nicola Waddell​295,296​, James S Wilmott​419​, Scott 
Wood​295,296​, Qinying Xu​295,296​ and Jean Y Yang​426 
 
PCAWG Tumour-specific providers (pancreatic cancer) in Canada 
John Bartlett​427,428​, Prashant Bavi​429​, Ivan Borozan​9​, Dianne E Chadwick​430​, Michelle 
Chan-Seng-Yue​429​, Sean Cleary​429,431​, Ashton A Connor​431,432​, Karolina Czajka​76​, Robert E 
Denroche​429​, Neesha C Dhani​433​, Jenna Eagles​76​, Vincent Ferretti​44,65​, Steven Gallinger​429,431,432​, 
Robert C Grant​429,432​, David Hedley​433​, Michael A Hollingsworth​434​, ​Thomas J Hudson​#​75,76​, Gun 
Ho Jang​429​, Jeremy Johns​76​, Sangeetha Kalimuthu​429​, Sheng-Ben Liang​430​, Ilinca Lungu​429,435​, 
Xuemei Luo​9​, Faridah Mbabaali​76​, ​John D McPherson​#​76,429,436​, Treasa A McPherson​432​, Jessica K 
Miller​76​, Malcolm J Moore​433​, Faiyaz Notta​429,437​, Danielle Pasternack​76​, Gloria M Petersen​438​, 
Michael H A Roehrl​125,429,430,439,440,441​, Michelle Sam​76​, Iris Selander​432​, Stefano Serra​394​, Sagedeh 
Shahabi​430​, ​Lincoln D Stein​#​9,10​, Morgan L Taschuk​44​, Sarah P Thayer​434​, Lee E Timms​76​, Gavin W 
Wilson ​9,429​, Julie M Wilson​429​ and Bradly G Wouters​125 
 
PCAWG Tumour-specific providers (prostate cancer) in Canada 
Timothy A Beck​44,442​, Vinayak Bhandari​9​, ​Paul C Boutros​#​9,125,134,135​, ​Robert G 
Bristow​#​125,443,444,445,446​, Colin C Collins​142​, Shadrielle MG Espiritu​9​, Neil E Fleshner​447​, Natalie S 
Fox​9​, Michael Fraser​9​, Syed Haider​9​, Lawrence E Heisler​44​, Vincent Huang​9​, Emilie Lalonde​9​, Julie 
Livingstone​9​, John D McPherson​76,429,436​, Alice Meng​448​, Veronica Y Sabelnykova​9​, Adriana 
Salcedo​9​, Yu-Jia Shiah​9​, Theodorus Van der Kwast​441​ and Takafumi N Yamaguchi​9 
 
PCAWG Tumour-specific providers (gastric cancer) in China 
Shuai Ding​449​, Daiming Fan​450​, Yong Hou​38,235​, Yi Huang​144,145​, Lin Li​38​, Siliang Li​38,235​, Dongbing 
Liu​38,235​, Xingmin Liu​38,235​, ​Youyong Lu​#​28,29,30​, Yongzhan Nie​450,451​, Hong Su​38,235​, Jian Wang​38​, Kui 
Wu​38,235​, Xiao Xiao​145​, Rui Xing​30​, ​Huanming Yang​#​38​, Shanlin Yang​449​, Yingyan Yu​452​, Xiuqing 
Zhang​38​, Yong Zhou​38​ and Shida Zhu​38,235 
 
PCAWG Tumour-specific providers (renal cancer) in the EU & France 
Rosamonde E Banks ​453​, Guillaume Bourque​454,455​, Alvis Brazma​7​, Paul Brennan​456​, ​Mark 
Lathrop​#​455​, Louis Letourneau​457​, Yasser Riazalhosseini​455​, Ghislaine Scelo​456​, ​Jörg Tost​#​458​, 
Naveen Vasudev​459​ and Juris Viksna​460 
 
PCAWG Tumour-specific providers (breast cancer) in the EU & 
United Kingdom 
Sung-Min Ahn​461​, Ludmil B Alexandrov​1,70,302​, Samuel Aparicio​462​, Laurent Arnould​463​, MR Aure​464​, 
Shriram G Bhosle​1​, Ewan Birney​7​, Ake Borg​465​, Sandrine Boyault​466​, Arie B Brinkman​467​, Jane E 
Brock​468​, Annegien Broeks​469​, Adam P Butler​1​, Anne-Lise Børresen-Dale​464,470​, Carlos Caldas​278,471​, 
Peter J Campbell​1,2​, Suet-Feung Chin​278,471​, Helen Davies​1,309,310​, Christine Desmedt​472,473​, Luc 
Dirix ​474​, Serge Serge​1​, Anna Ehinger​475​, Jorunn E Eyfjord​476​, Aquila Fatima​204​, John A Foekens​477​, P 
Andrew Futreal​478​, Øystein Garred​479,480​, Moritz Gerstung​7,8​, Dilip D Giri​481​, Dominik Glodzik​1​, 
Dorthe Grabau​482​, Holmfridur Hilmarsdottir​476​, Gerrit K Hooijer​483​, Jocelyne Jacquemier​484​, Se Jin 
Jang​485​, Jon G Jonasson​476​, Jos Jonkers​486​, Hyung-Yong Kim​484​, Tari A King​487,488,489​, Stian 
Knappskog​1,490​, Gu Kong​484​, Savitri Krishnamurthy​352,491​, Sunil R Lakhani​492​, Anita Langerød​464​, 
Denis Larsimont​493​, Hee Jin Lee​485​, Jeong-Yeon Lee​494​, Ming Ta Michael Lee​478​, Yilong Li​1​, Ole 
Christian Lingjærde​495​, Gaetan MacGrogan​496​, John WM Martens​477​, Sancha Martin​1,353​, Iñigo 
Martincorena​1​, Andrew Menzies​1​, Sandro Morganella​1​, Ville Mustonen​305,306,307​, Serena 
Nik-Zainal​1,309,310,311​, Sarah O'Meara​1​, Iris Pauporté​20​, Sarah Pinder​497​, Xavier Pivot​498​, Elena 
Provenzano​499​, Colin A Purdie​500​, Keiran M Raine​1​, Manasa Ramakrishna​1​, Kamna 
Ramakrishnan​1​, Jorge Reis-Filho​481​, Andrea L Richardson​204​, Markus Ringnér​501​, Javier Bartolomé 
Rodriguez​45​, F Germán Rodríguez-González​502​, Gilles Romieu​503​, Roberto Salgado​394​, Torill 
Sauer​495​, Rebecca Shepherd​1​, Anieta M Sieuwerts​477​, Peter T Simpson​492​, Marcel Smid​477​, 
Christos Sotiriou​53​, Paul N Span​504​, Lucy Stebbings​1​, Ólafur Andri Stefánsson​505​, Alasdair 
Stenhouse​506​, ​Michael R Stratton​#​1​, Henk G Stunnenberg​235,507​, Fred Sweep​508​, Benita Kiat Tee 
Tan​509​, Jon W Teague​1​, Gilles Thomas​510​, Alastair M Thompson​506​, Stefania Tommasi​511​, Isabelle 
Treilleux​512,513​, Andrew Tutt​204​, Naoto T Ueno​514​, Steven Van Laere​474​, Peter Van Loo​60,61​, Gert G 
Van den Eynden​474​, Peter Vermeulen​474​, Alain Viari​400​, Anne Vincent-Salomon​507​, David C 
Wedge​1,340,341​, Bernice H Wong​515​, Lucy Yates​1​, Xueqing Zou​1​, Carolien HM van Deurzen​516​, Marc J 
van de Vijver​394​ and L van't Veer​517 
 
PCAWG Tumour-specific providers (malignant lymphoma) in 
Germany 
Ole Ammerpohl​518,519​, Sietse Aukema​520,521​, Anke K Bergmann​522​, Stephan H Bernhart​260,261,264​, 
Hans Binder​260,261​, Arndt Borkhardt​523​, Christoph Borst​524​, Benedikt Brors​79,112,262​, Birgit 
Burkhardt​525​, Alexander Claviez​526​, Roland Eils​50,52,63,64​, Maria Elisabeth Goebler​527​, Andrea 
Haake​518​, Siegfried Haas​524​, Martin Hansmann​528​, Jessica I Hoell​523​, Steve Hoffmann​260,261,263,264​, 
Michael Hummel​529​, Daniel Hübschmann​52,63,80,81,82​, Dennis Karsch​530​, Wolfram Klapper​520​, Kortine 
Kleinheinz​50,52​, Michael Kneba​530​, Jan O Korbel​7,8​, Helene Kretzmer​261,264​, Markus Kreuz​531​, Dieter 
Kube​532​, Ralf Küppers​533​, Chris Lawerenz​64​, Dido Lenze​529​, Peter Lichter​77,386​, Markus Loeffler​531​, 
Cristina López ​246,518​, Luisa Mantovani-Löffler​534​, Peter Möller​535​, German Ott​536​, Bernhard 
Radlwimmer​386​, Julia Richter​518,520​, Marius Rohde​537​, Philip C Rosenstiel​538​, Andreas Rosenwald​539​, 
Markus B Schilhabel​538​, Matthias Schlesner​50,102​, Stefan Schreiber​540​, ​Reiner Siebert​#​245,246​, Peter 
F Stadler​260,261,264​, Peter Staib​541​, Stephan Stilgenbauer​542​, Stephanie Sungalee​8​, Monika 
Szczepanowski​520​, Umut H Toprak​52,543​, Lorenz HP Trümper​532​, Rabea Wagener​246,518​ and 
Thorsten Zenz​79 
 
PCAWG Tumour-specific providers (paediatric brain cancer) in 
Germany 
Ivo Buchhalter​50,51,52​, Juergen Eils​63,64​, Roland Eils​50,52,63,64​, Volker Hovestadt​386​, Barbara 
Hutter​77,78,79​, David TW Jones​285,286​, Natalie Jäger​50​, Christof von Kalle​81​, Marcel Kool​93,285​, Jan O 
Korbel​7,8​, Andrey Korshunov​93​, Pablo Landgraf​544,545​, Chris Lawerenz​64​, Hans Lehrach​546​, ​Peter 
Lichter​#​77,386​, Paul A Northcott​547​, Stefan M Pfister​93,285,548​, Bernhard Radlwimmer​386​, Guido 
Reifenberger​545​, Matthias Schlesner​50,102​, Hans-Jörg Warnatz​546​, Joachim Weischenfeldt​8,107,108​, 
Stephan Wolf​549​, Marie-Laure Yaspo​546​ and Marc Zapatka​386 
 
PCAWG Tumour-specific providers (prostate cancer) in Germany 
Yassen Assenov​550​, Benedikt Brors​79,112,262​, Juergen Eils​63,64​, Roland Eils​50,52,63,64​, Lars Feuerbach​112​, 
Clarissa Gerhauser​268​, Jan O Korbel​7,8​, Chris Lawerenz​64​, Hans Lehrach​546​, Sarah Minner​551​, 
Christoph Plass​268​, ​Guido Sauter​#​552​, Thorsten Schlomm​107,553​, Nikos Sidiropoulos​108​, Ronald 
Simon​552​, ​Holger Sültmann​#​79,554​, Hans-Jörg Warnatz​546​, Dieter Weichenhan​268​, Joachim 
Weischenfeldt​8,107,108​ and Marie-Laure Yaspo​546 
 
PCAWG Tumour-specific providers (oral cancer) in India 
Nidhan K Biswas​555​, Luca Landoni​396​, Arindam Maitra​555​, ​Partha P Majumder​#​555​ and ​Rajiv 
Sarin ​#​556 
 
PCAWG Tumour-specific providers (pancreatic cancer) in Italy 
Davide Antonello​396​, Stefano Barbi​403​, Claudio Bassi​396​, Samantha Bersani​399​, Giada Bonizzato​400​, 
Cinzia Cantù​400​, Ivana Cataldo​399,400​, Sara Cingarlini​36​, Vincenzo Corbo​400,403​, Maria Vittoria Davi​404​, 
Angelo P Dei Tos​557​, Matteo Fassan​558​, Sonia Grimaldi​400​, Luca Landoni​396​, Rita T Lawlor​400​, 
Claudio Luchini​399​, Andrea Mafficini​400​, Giuseppe Malleo​396​, Giovanni Marchegiani​396​, Michele 
Milella​36​, Marco Miotto​396​, Salvatore Paiella​396​, Antonio Pea​396​, Paolo Pederzoli​396​, Borislav C 
Rusev​400​, Andrea Ruzzenente​396​, Roberto Salvia​396​, Maria Scardoni​399​, ​Aldo Scarpa​#​400​, Elisabetta 
Sereni​396​, Michele Simbolo​403​, Nicola Sperandio​400​, Giampaolo Tortora​36,37​ and Caterina 
Vicentini​400 
 
PCAWG Tumour-specific providers (biliary tract cancer) in Japan 
Yasuhito Arai​33​, Natsuko Hama​33​, Nobuyoshi Hiraoka​559​, Fumie Hosoda​33​, Mamoru Kato​351​, 
Hiromi Nakamura​33​, Hidenori Ojima​560​, Takuji Okusaka​561​, ​Tatsuhiro Shibata​#​33,34​, Yasushi 
Totoki​33​ and Tomoko Urushidate​34 
 
PCAWG Tumour-specific providers (gastric cancer) in Japan 
Hiroyuki Aburatani​#​256​, Yasuhito Arai​33​, Masashi Fukayama​562​, Natsuko Hama​33​, Fumie 
Hosoda​33​, Shumpei Ishikawa​563​, Hitoshi Katai​564​, Mamoru Kato​351​, Hiroto Katoh​563​, Daisuke 
Komura​563​, Genta Nagae​256,267​, Hiromi Nakamura​33​, Hirofumi Rokutan​351​, Mihoko Saito-Adachi​351​, 
Tatsuhiro Shibata​#​33,34​, Akihiro Suzuki​256,565​, Hirokazu Taniguchi​34​, Kenji Tatsuno​256​, Yasushi 
Totoki​33​, Tetsuo Ushiku​562​, Shinichi Yachida​33,566​ and Shogo Yamamoto​256 
 
PCAWG Tumour-specific providers (liver cancer) in Japan 
Hiroyuki Aburatani​256​, Hiroshi Aikata​567​, Koji Arihiro​567​, Shun-ichi Ariizumi​568​, Keith A 
Boroevich​46,47​, Kazuaki Chayama​567​, Akihiro Fujimoto​47​, Masashi Fujita​47​, Mayuko Furuta​47​, 
Kunihito Gotoh​569​, Natsuko Hama​33​, Takanori Hasegawa​83​, Shinya Hayami​570​, Shuto Hayashi​83​, 
Satoshi Hirano​571​, Seiya Imoto​83​, Mamoru Kato​351​, Yoshiiku Kawakami​567​, Kazuhiro Maejima​47​, 
Satoru Miyano​83​, Genta Nagae​256,267​, ​Hidewaki Nakagawa​#​47​, Hiromi Nakamura​33​, Toru 
Nakamura​571​, Kaoru Nakano​47​, Hideki Ohdan​567​, Yasushi Rino​572​, Aya Sasaki-Oku​47​, ​Tatsuhiro 
Shibata ​#​33,34​, Yuichi Shiraishi​83​, Hiroko Tanaka​83​, Yasushi Totoki​33​, Tatsuhiko Tsunoda​46,207,208,209​, 
Masaki Ueno ​570​, Rui Yamaguchi​83​, Masakazu Yamamoto​568​ and Hiroki Yamaue​570 
 
PCAWG Tumour-specific providers (biliary tract cancer) in Singapore 
Su Pin Choo​573​, Ioana Cutcutache​251,304​, Narong Khuntikeo​396,574​, John R McPherson​251,304​, Choon 
Kiat Ong​575​, Chawalit Pairojkul​394​, Irinel Popescu​576​, ​Steven G Rozen​#​251,252,304​, ​Patrick 
Tan ​#​239,250,251,252​ and ​Bin Tean Teh​#​250,251,252,253,254 
 
PCAWG Tumour-specific providers (blood cancer) in South Korea 
Keun Soo Ahn​577​, Hyung-Lae Kim​27​, Youngil Koh​291,292​ and ​Sung-Soo Yoon​#​292 
 
PCAWG Tumour-specific providers (chronic lymphocytic leukaemia) 
in Spain 
Marta Aymerich​578​, ​Elias Campo​#​579,580​, Josep L L Gelpi​45,67​, Ivo G Gut​127,128​, Marta Gut​127,128​, 
Armando Lopez-Guillermo​581​, Carlos López-Otín​582​, Xose S Puente​582​, Romina Royo​45​ and David 
Torrents​45,105 
 
PCAWG Tumour-specific providers (bone cancer) in the United 
Kingdom 
Fernanda Amary​583​, Daniel Baumhoer​584​, Sam Behjati​1​, Bodil Bjerkehagen​584,585​, ​Peter J 
Campbell​#​1,2​, ​Adrienne M Flanagan​#​586​, P Andrew Futreal​478​, Ola Myklebost​490​, Nischalan 
Pillay​587​, Patrick Tarpey​588​, Roberto Tirabosco​589​ and Olga Zaikova​590 
 
PCAWG Tumour-specific providers (chronic myeloid disorders) in the 
United Kingdom 
Jacqueline Boultwood​591​, David T Bowen​1​, Adam P Butler​1​, ​Peter J Campbell​#​1,2​, Mario 
Cazzola​592​, Carlo Gambacorti-Passerini​177​, Anthony R Green​279​, Eva Hellstrom-Lindberg​593​, Luca 
Malcovati​592​, Sancha Martin​1,353​, Jyoti Nangalia​1​, Elli Papaemmanuil​2​ and Paresh Vyas​295,594 
 
PCAWG Tumour-specific providers (oesophageal cancer) in the 
United Kingdom 
Yeng Ang​595​, Hugh Barr​596​, Duncan Beardsmore​597​, Matthew Eldridge​278​, ​Rebecca C 
Fitzgerald​#​310​, James Gossage​598​, Nicola Grehan​310​, George B Hanna​599​, Stephen J Hayes​600,601​, 
Ted R Hupp​602​, David Khoo​603​, Jesper Lagergren​593,604​, Laurence B Lovat​237​, Shona MacRae​375​, 
Maria O'Donovan​310​, J Robert O'Neill​605​, Simon L Parsons​606​, Shaun R Preston​607​, Sonia Puig​608​, 
Tom Roques​609​, Grant Sanders​234​, Sharmila Sothi​610​, Simon Tavaré​278​, Olga Tucker​611​, Richard 
Turkington​612​, Timothy J Underwood​613​ and Ian Welch​614 
 
PCAWG Tumour-specific providers (prostate cancer) in the United 
Kingdom 
Daniel M Berney​615​, Johann S De Bono​383​, G Steven Bova​316​, Daniel S Brewer​381,382​, Adam P 
Butler​1​, Declan Cahill​616​, Niedzica Camacho​383​, ​Colin S Cooper​#​382,383,384​, Nening M Dennis​616​, Tim 
Dudderidge​616,617​, Sandra E Edwards​383​, ​Rosalind A Eeles​#​383,616​, Cyril Fisher​616​, Christopher S 
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